GTC Biotherapeutics (fka GTCB)

[ThomasS]

In that context, and given ATRYN's likely average pricing across the EU, the addressable market size for EU should equal @ $5-6 Billion. Even with a royalty-only arrangement, this rev stream would be quite consequential if ATRYN captured 1/3, (similiar to the USA forecast) for example.
The total World-wide addressable market should be well in excess of $10B.
If it works in DIC, of course ;)